menu
    • menu
    [{"orgOrder":0,"company":"Kynexis Therapeutics","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KYN-5356","moa":"KAT2","graph1":"Neurology","graph2":"Phase I","graph3":"Kynexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kynexis Therapeutics \/ Parexel","highestDevelopmentStatusID":"6","companyTruncated":"Kynexis Therapeutics \/ Parexel"},{"orgOrder":0,"company":"Kynexis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KYN-5356","moa":"KAT2","graph1":"Neurology","graph2":"Phase I","graph3":"Kynexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kynexis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kynexis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kynexis Therapeutics","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2023","type":"Series A Financing","leadProduct":"KYN-5356","moa":"KAT2","graph1":"Neurology","graph2":"Phase I","graph3":"Kynexis Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Kynexis Therapeutics \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Kynexis Therapeutics \/ Forbion"},{"orgOrder":0,"company":"Kynexis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KYN-5356","moa":"KAT2","graph1":"Neurology","graph2":"Phase I","graph3":"Kynexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kynexis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kynexis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kynexis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"KYN-5356","moa":"KAT2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Kynexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kynexis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kynexis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kynexis Therapeutics","sponsor":"Cognision","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Partnership","leadProduct":"KYN-5356","moa":"KAT2","graph1":"Undisclosed","graph2":"Approved FDF","graph3":"Kynexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kynexis Therapeutics \/ Kynexis Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Kynexis Therapeutics \/ Kynexis Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Kynexis Therapeutics

    Menu

    Kynexis Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kynexis Therapeutics

                            Netherlands arrow
                            BioFit
                            Not Confirmed

                            Kynexis Therapeutics

                            Netherlands arrow
                            BioFit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KYN-5356

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Recipient : Cognision

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Cognision Partners with Kynexis for Phase 2 Trial of KYN-5356 in Schizophrenia Subjects

                            Details : The partnership with KYN-5356 aims to advance the treatment of neurological disorders by targeting KAT2.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 14, 2025

                            Lead Product(s) : KYN-5356

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Recipient : Cognision

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kynexis Therapeutics

                            Netherlands arrow
                            BioFit
                            Not Confirmed

                            Kynexis Therapeutics

                            Netherlands arrow
                            BioFit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KYN-5356

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia

                            Details : KYN-5356 is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Cognitive Dysfunction-associated with Schizophrenia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 24, 2025

                            Lead Product(s) : KYN-5356

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kynexis Therapeutics

                            Netherlands arrow
                            BioFit
                            Not Confirmed

                            Kynexis Therapeutics

                            Netherlands arrow
                            BioFit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KYN-5356

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kynexis Reports Topline Results of KYN-5356 for Cognitive Impairment in Schizophrenia

                            Details : KYN-5356 is a small molecule targeting a key enzyme in the kynurenine pathway known as KAT-II. It is being evaluated for the treatment of cognitive impairment associated with schizophrenia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 17, 2024

                            Lead Product(s) : KYN-5356

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kynexis Therapeutics

                            Netherlands arrow
                            BioFit
                            Not Confirmed

                            Kynexis Therapeutics

                            Netherlands arrow
                            BioFit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KYN-5356

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Parexel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 ...

                            Details : KYN-5356 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cognitive Dysfunction.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 25, 2024

                            Lead Product(s) : KYN-5356

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Parexel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kynexis Therapeutics

                            Netherlands arrow
                            BioFit
                            Not Confirmed

                            Kynexis Therapeutics

                            Netherlands arrow
                            BioFit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KYN-5356

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kynexis Initiates Phase 1 Study Of KYN-5356 for Cognitive Impairment in Schizophrenia

                            Details : KYN-5356 is a clinical-stage small molecule targeting KAT-II in the kynurenine pathway. It is being evaluated in Phase 1 for cognitive impairment associated with schizophrenia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 04, 2024

                            Lead Product(s) : KYN-5356

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Kynexis Therapeutics

                            Netherlands arrow
                            BioFit
                            Not Confirmed

                            Kynexis Therapeutics

                            Netherlands arrow
                            BioFit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KYN-5356

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Forbion

                            Deal Size : $62.1 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Kynexis Launched to Advance Precision Therapeutics for Brain Diseases

                            Details : Through the proceeds, Kynexis will advance its lead therapeutic candidate, KYN-5356, a potential first-in-class KAT-II inhibitor for the treatment of cognitive impairment associated with schizophrenia (CIAS), toward clinical development.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 07, 2023

                            Lead Product(s) : KYN-5356

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Forbion

                            Deal Size : $62.1 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth